All News

arthritis.RA_.Xray_.hands_.jpg (keep)

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

d Jack Cush, MD

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.

Read Article

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants

d Jack Cush, MD

The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.

Read Article
WAR.RA_.jpg

War on RA - Part 1: Walk on the Moon

d Jack Cush, MD

It’s a great time to be a rheumatologist and to manage RA. But, if you keep doing what you’re doing, you’re going to keep getting what you’ve got.

Read Article
knee.surgery.jpg (keep)

Partial or Total Knee Replacement for Osteoarthritis?

d Jack Cush, MD

Lancet has reported on a clinical trial comparing total knee replacement (TKR) and partial knee replacement (PKR) in late-stage isolated medial compartment knee osteoarthritis patients finding that both TKR and PKR are equally effective, PKR should be considered the first, because of lower costs

Read Article
FDA.approved.jpg

FDA Approves Apremilast for Behcet's Oral Ulcers

d Jack Cush, MD

The US Food and Drug Administration (FDA) has approved apremilast (Otezla) for the treatment of oral ulcers associated with Behçet’s Disease, a rare chronic multisystem inflammatory disease that affects about 5 in 100,000 persons in the USA.

Read Article
FDA has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan for use in NHL, CLL, granulomatosis w/ polyangiitis (GPA) & microscopic polyangiitis;(NOT RA) THis is the 2nd RTX biosimilar. https://t.co/GuVG6S980j

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Arthritis Advisory Committee (AAC) and Drug Safety Committees are meeting today in Hyattsville to consider the approval of nintedanib (OFEV, made by BI), for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/z4uLJ8hdyX

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA warning about meds that may impair driving (car, bus, train, plane, or boat) - Especially opioids, benzodiazepines, antidepressants, muscle relaxants, sleep meds, motion sickness & diet pills, ADD or “stay awake” drugs https://t.co/P08wvds0GK

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved a new biosimilar Hadlima (adalimumab-bwwd), from Samsung Bioepis, for the same indications as Humira (RA, pJIA, PsA, AS, Crohn’s, UC, plaque psoriasis), but the drug won't be available in the U.S. until June 2023. https://t.co/h4oqwFjR0c

Links:

Dr. John Cush RheumNow ( View Tweet)

Im starting a War on RA. I need you go get mad. Read it here https://t.co/sR5Z3lq8CU or watch it here https://t.co/s7CVW2dNUT

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA approves generic pregabalin (Lyrica) - for the management of fibromyalgia, neuropathic pain in diabetic neuropathy, and for postherpetic neuralgia or partial onset seizures & neuropathic pain associated with spinal cord injury. https://t.co/Jg5q7LLjT2

Links:

Dr. John Cush RheumNow ( View Tweet)

EUSTAR Study had 1451 systemic sclerosis (SSc) pts enrolled & 706 had complete data. Predictors of #SSc worsening included age, active digital ulcers, lung fibrosis, muscle weakness and elevated C-reactive protein level. https://t.co/QepC6I0HLm

Links:

Dr. John Cush RheumNow ( View Tweet)

18 mos study of 78 patients with ANCA Assoc Vasculitis showed baseline IL-6 levels correlate with PR3-ANCA (not MPO) titers; while assoc w/ certain Sxs (fever, pulm nodules/cavities), deafness, RBC casts; sIL6 levels did not predict responses at 6 mos https://t.co/jawVLOSQnZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Dannish MRI study of 204 people (including 41 #AxSpA) shows that sacroiliac bone marrow edema is nonspecific, seen in 3-39% of non-SpA. Only SI erosions erosions, backfill & ankylosis were specific for axSpA. Few women w/ postpartum pain had SI erosion https://t.co/7iMaKGEafJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Weight loss does not reduce #RA risk. Swedish Obese (SOS) study followed 2002 bariatric surgery pts & 2034 controls. Overall 92 developed RA; RA risk now lower w/ bariatric surgery (HR 0.92; CI 0.59, 1.46) nor did wt loss; but CRP & smoking were https://t.co/bFKiPWvKRQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Study from National Inpatient Sample (2002-11) , 424 hospitals, 4024 #SLE pts admitted w/ sepsis. Mortality varied from 0-60%. Hospitals that treated ⩾3.9 patients with SLE and sepsis annually had a lower risk of lupus mortality (10% vs 17%; P = 0.004). https://t.co/TuVfaGUpcM

Links:

Dr. John Cush RheumNow ( View Tweet)

Mayo Clinic study shows that once #RA is diagnosed with CHF, hospitalization rates were significantly higher in RA vs non-RA (RR 1.17; CI 1.08-1.26). RA \more likely to be hospitalized for non-cardiovascular (RR 1.26); not for CHF or other CV causes. https://t.co/r5fvygpAE9

Links:

Dr. John Cush RheumNow ( View Tweet)

40 years since the "House of God" by Samuel Shem, Dr. Len Calabrese's recollects on the books 40th anniversary. Join his summer book club and add some commentary! https://t.co/L8wiGpWk42

Links:

Dr. John Cush RheumNow ( View Tweet)

Nearly half of Americans believe that the U.S. health care and health care providers are not compassionate. Studies show less than half of physicians and clergy exhibit compassion. (from COMPASSIONOMICS by Trseciak & Mazzarelli) https://t.co/z0F7Ql5oR3

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up! Discussions on MDA-5 Abs & DM; gout & narcotics; IA capsaicin in OA; and ADA vs UPA. Watch here>> https://t.co/gZRJ2eHCqB or listen on iTunes or SoundCloud>> https://t.co/x6mCEqg6gU

Links:

Dr. John Cush RheumNow ( View Tweet)

×